{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:37:10Z","timestamp":1789040230382,"version":"build-2803163510"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vaccine and Treatment Evaluation Unit","award":["HHSN272201300022I"],"award-info":[{"award-number":["HHSN272201300022I"]}]},{"name":"Vaccine and Treatment Evaluation Unit","award":["K23AI155838"],"award-info":[{"award-number":["K23AI155838"]}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001949","name":"American Society of Tropical Medicine and Hygiene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003240","name":"Passano Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003240","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Plasmodium falciparum circumsporozoite protein (CSP) is the target of multiple malaria vaccines that include only a part of the protein, such as RTS,S and R21. The monoclonal antibodies L9 and CIS43 are directed against key CSP junctional region epitopes not included in RTS,S and R21, and next-generation vaccine candidates attempt to elicit similar antibodies. Understanding the effectiveness of multiple antibody responses against CSP peptides will inform next-generation vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using serum samples collected during controlled human malaria infection experiments that evaluated vaccine efficacy, we used a peptide array inclusive of CSP genetic variants to quantify anti-CSP antibody responses in unprotected adults who received a full-length recombinant CSP vaccine (rCSP), protected adults who received RTS,S, and unprotected adults who received RTS,S. We compared the breadth and intensity of responses to CSP variants between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, rCSP recipients had lower CSP antibody responses compared with the protected RTS,S group. Compared with the unprotected groups, protected RTS,S vaccinees had higher breadth of responses to peptides in the junctional region, central repeat region, and C-terminal region. The protected RTS,S group also had higher intensity of responses to 2 C-terminal peptides, including part of Th3R. In addition, protected RTS,S recipients had higher breadth of immunoglobulin A responses to variants of the C-terminal epitope PNDPNRNV, identified as a dominant motif by motif recognition software, and to similar sequences in the junctional region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Protection-associated antibody responses to the junctional region not contained in RTS,S suggest a cross-reactive, vaccine-induced response that provides additional benefit beyond antibodies targeting vaccine peptides.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf391","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T11:53:03Z","timestamp":1755258783000},"page":"178-190","source":"Crossref","is-referenced-by-count":1,"title":["Vaccine-Induced Antibodies to a C-Terminal\n                    <i>Plasmodium falciparum<\/i>\n                    Circumsporozoite Protein Epitope Associated With Protection Against Malaria Challenge"],"prefix":"10.1093","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0373-4643","authenticated-orcid":false,"given":"DeAnna J","family":"Friedman-Klabanoff","sequence":"first","affiliation":[{"name":"Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-0469","authenticated-orcid":false,"given":"Travis L","family":"Jensen","sequence":"additional","affiliation":[{"name":"Bioinformatics & Data Science, The Emmes Company , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey E","family":"Gelber","sequence":"additional","affiliation":[{"name":"Bioinformatics & Data Science, The Emmes Company , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7763-4800","authenticated-orcid":false,"given":"Richard S","family":"Pinapati","sequence":"additional","affiliation":[{"name":"Nimble Therapeutics , Madison, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"Tan","sequence":"additional","affiliation":[{"name":"Nimble Therapeutics , Madison, Wisconsin ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5527-4541","authenticated-orcid":false,"given":"Gregory A","family":"Deye","sequence":"additional","affiliation":[{"name":"Parasitology and International Programs Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9928-221X","authenticated-orcid":false,"given":"Jason A","family":"Regules","sequence":"additional","affiliation":[{"name":"Biologics Research & Development, Walter Reed Army Institute of Research , Silver Spring, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8571-8956","authenticated-orcid":false,"given":"Elke S","family":"Bergmann-Leitner","sequence":"additional","affiliation":[{"name":"Biologics Research & Development, Walter Reed Army Institute of Research , Silver Spring, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3874-581X","authenticated-orcid":false,"given":"Matthew B","family":"Laurens","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6045-3322","authenticated-orcid":false,"given":"Mark A","family":"Travassos","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes B","family":"Goll","sequence":"additional","affiliation":[{"name":"Bioinformatics & Data Science, The Emmes Company , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Takala-Harrison","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3140-3868","authenticated-orcid":false,"given":"Andrea A","family":"Berry","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development and Global Health, University of Maryland School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"2026041420080403700_jiaf391-B1","doi-asserted-by":"crossref","DOI":"10.30875\/9789287076717","volume-title":"World malaria report 2024: addressing inequity in the global malaria response","author":"World Health Organization","year":"2024"},{"key":"2026041420080403700_jiaf391-B2","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children","volume":"365","author":"Agnandji","year":"2011","journal-title":"N Engl J Med"},{"key":"2026041420080403700_jiaf391-B3","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(24)00004-7","article-title":"Feasibility, safety, and impact of the RTS,S\/AS01(E) malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi","volume":"403","author":"Asante","year":"2024","journal-title":"Lancet"},{"key":"2026041420080403700_jiaf391-B4","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.1074\/jbc.M106862200","article-title":"Binding and invasion of liver cells by Plasmodium falciparum sporozoites: essential involvement of the amino terminus of circumsporozoite protein","volume":"277","author":"Rathore","year":"2002","journal-title":"J. Biol. Chem"},{"key":"2026041420080403700_jiaf391-B5","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.vaccine.2020.12.023","article-title":"Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing","volume":"39","author":"Friedman-Klabanoff","year":"2021","journal-title":"Vaccine"},{"key":"2026041420080403700_jiaf391-B6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"key":"2026041420080403700_jiaf391-B7","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.4512","article-title":"A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite","volume":"24","author":"Kisalu","year":"2018","journal-title":"Nat Med"},{"key":"2026041420080403700_jiaf391-B8","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.immuni.2020.08.014","article-title":"A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver","volume":"53","author":"Wang","year":"2020","journal-title":"Immunity"},{"key":"2026041420080403700_jiaf391-B9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa2034031","article-title":"A monoclonal antibody for malaria prevention","volume":"385","author":"Gaudinski","year":"2021","journal-title":"N Engl J Med"},{"key":"2026041420080403700_jiaf391-B10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMoa2203067","article-title":"Low-dose subcutaneous or intravenous monoclonal antibody to prevent malaria","volume":"387","author":"Wu","year":"2022","journal-title":"N Engl J Med"},{"key":"2026041420080403700_jiaf391-B11","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1473-3099(22)00793-9","article-title":"Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial","volume":"23","author":"Lyke","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026041420080403700_jiaf391-B12","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1056\/NEJMoa2206966","article-title":"Safety and efficacy of a monoclonal antibody against malaria in Mali","volume":"387","author":"Kayentao","year":"2022","journal-title":"N Engl J Med"},{"key":"2026041420080403700_jiaf391-B13","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1056\/NEJMoa2312775","article-title":"Subcutaneous administration of a monoclonal antibody to prevent malaria","volume":"390","author":"Kayentao","year":"2024","journal-title":"N Engl J Med"},{"key":"2026041420080403700_jiaf391-B14","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/infdis\/jiv224","article-title":"Plasmodium falciparum protein microarray antibody profiles correlate with protection from symptomatic malaria in Kenya","volume":"212","author":"Dent","year":"2015","journal-title":"J Infect Dis"},{"key":"2026041420080403700_jiaf391-B15","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1002\/pmic.200800194","article-title":"Profiling humoral immune responses to P. falciparum infection with protein microarrays","volume":"8","author":"Doolan","year":"2008","journal-title":"Proteomics"},{"key":"2026041420080403700_jiaf391-B16","doi-asserted-by":"crossref","first-page":"M111 007948","DOI":"10.1074\/mcp.M111.007948","article-title":"Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens","volume":"10","author":"Trieu","year":"2011","journal-title":"Mol Cell Proteomics"},{"key":"2026041420080403700_jiaf391-B17","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1038\/srep03549","article-title":"Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis","volume":"3","author":"Felgner","year":"2013","journal-title":"Sci Rep"},{"key":"2026041420080403700_jiaf391-B18","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa1505819","article-title":"Genetic diversity and protective efficacy of the RTS,S\/AS01 malaria vaccine","volume":"373","author":"Neafsey","year":"2015","journal-title":"N Engl J Med"},{"key":"2026041420080403700_jiaf391-B19","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.vaccine.2020.12.055","article-title":"Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria vaccine","volume":"39","author":"Chaudhury","year":"2021","journal-title":"Vaccine"},{"key":"2026041420080403700_jiaf391-B20","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3390\/microorganisms10061090","article-title":"An in silico analysis of malaria pre-erythrocytic-stage antigens interpreting worldwide genetic data to suggest vaccine candidate variants and epitopes","volume":"10","author":"Ouattara","year":"2022","journal-title":"Microorganisms"},{"key":"2026041420080403700_jiaf391-B21","doi-asserted-by":"crossref","first-page":"e101783","DOI":"10.1371\/journal.pone.0101783","article-title":"Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications","volume":"9","author":"Gandhi","year":"2014","journal-title":"PLoS One"},{"key":"2026041420080403700_jiaf391-B22","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","article-title":"Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial","volume":"15","author":"White","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2026041420080403700_jiaf391-B23","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1038\/s41467-019-10195-z","article-title":"Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S\/AS01E malaria vaccine efficacy","volume":"10","author":"Doba\u00f1o","year":"2019","journal-title":"Nat Commun"},{"key":"2026041420080403700_jiaf391-B24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12916-018-1186-4","article-title":"Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S\/AS01E vaccination in African children","volume":"16","author":"Ubillos","year":"2018","journal-title":"BMC Med"},{"key":"2026041420080403700_jiaf391-B25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/600120","article-title":"Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection","volume":"200","author":"Kester","year":"2009","journal-title":"J Infect Dis"},{"key":"2026041420080403700_jiaf391-B26","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0140-6736(04)17223-1","article-title":"Efficacy of the RTS,S\/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial","volume":"364","author":"Alonso","year":"2004","journal-title":"Lancet"},{"key":"2026041420080403700_jiaf391-B27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12936-016-1348-9","article-title":"The biological function of antibodies induced by the RTS,S\/AS01 malaria vaccine candidate is determined by their fine specificity","volume":"15","author":"Chaudhury","year":"2016","journal-title":"Malar J"},{"key":"2026041420080403700_jiaf391-B28","doi-asserted-by":"crossref","first-page":"1303446","DOI":"10.3389\/fimmu.2023.1303446","article-title":"Novel antibody competition binding assay identifies distinct serological profiles associated with protection","volume":"14","author":"Bolton","year":"2023","journal-title":"Front Immunol"},{"key":"2026041420080403700_jiaf391-B29","doi-asserted-by":"crossref","first-page":"eabb4757","DOI":"10.1126\/scitranslmed.abb4757","article-title":"Mapping functional humoral correlates of protection against malaria challenge following RTS,S\/AS01 vaccination","volume":"12","author":"Suscovich","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026041420080403700_jiaf391-B30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41541-021-00363-y","article-title":"Immunoprofiles associated with controlled human malaria infection and naturally acquired immunity identify a shared IgA pre-erythrocytic immunoproteome","volume":"6","author":"Berry","year":"2021","journal-title":"NPJ Vaccines"},{"key":"2026041420080403700_jiaf391-B31","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.vaccine.2020.12.038","article-title":"RTS,S\/AS01(E) malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial","volume":"39","author":"Suau","year":"2021","journal-title":"Vaccine"},{"key":"2026041420080403700_jiaf391-B32","doi-asserted-by":"crossref","first-page":"100898","DOI":"10.1016\/S2666-5247(24)00130-7","article-title":"Antibody mechanisms of protection against malaria in RTS,S-vaccinated children: a post-hoc serological analysis of phase 2 trial","volume":"5","author":"Kurtovic","year":"2024","journal-title":"Lancet Microbe"},{"key":"2026041420080403700_jiaf391-B33","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/infdis\/jiae062","article-title":"Recombinant full-length Plasmodium falciparum circumsporozoite protein-based vaccine adjuvanted with GLA-LSQ: results of phase 1 testing with malaria challenge","volume":"229","author":"Friedman-Klabanoff","year":"2024","journal-title":"J Infect Dis"},{"key":"2026041420080403700_jiaf391-B34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0923-2494(94)80178-9","article-title":"Effect of polymorphism of sporozoite antigens on T-cell activation","volume":"145","author":"Zevering","year":"1994","journal-title":"Res Immunol"},{"key":"2026041420080403700_jiaf391-B35","doi-asserted-by":"crossref","first-page":"12116","DOI":"10.1038\/s41598-017-12440-1","article-title":"Stepwise evolution improves identification of diverse peptides binding to a protein target","volume":"7","author":"Lyamichev","year":"2017","journal-title":"Sci Rep"},{"key":"2026041420080403700_jiaf391-B36","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.41089","article-title":"Comprehensive profiling of the rheumatoid arthritis antibody repertoire","volume":"72","author":"Lo","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2026041420080403700_jiaf391-B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2013.06.001","article-title":"A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling","volume":"395","author":"Imholte","year":"2013","journal-title":"J Immunol Methods"},{"key":"2026041420080403700_jiaf391-B38","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/infdis\/jiaa611","article-title":"Epitope-specific antibody responses to a Plasmodium falciparum subunit vaccine target in a malaria-endemic population","volume":"223","author":"Friedman-Klabanoff","year":"2021","journal-title":"J Infect Dis"},{"key":"2026041420080403700_jiaf391-B39","doi-asserted-by":"crossref","first-page":"W202","DOI":"10.1093\/nar\/gkp335","article-title":"MEME Suite: tools for motif discovery and searching","volume":"37","author":"Bailey","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"2026041420080403700_jiaf391-B40","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/gb-2007-8-2-r24","article-title":"Quantifying similarity between motifs","volume":"8","author":"Gupta","year":"2007","journal-title":"Genome Biol"},{"key":"2026041420080403700_jiaf391-B41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41541-022-00430-y","article-title":"Restricted valency (NPNA)(n) repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum","volume":"7","author":"Langowski","year":"2022","journal-title":"NPJ Vaccines"},{"key":"2026041420080403700_jiaf391-B42","doi-asserted-by":"crossref","first-page":"108996","DOI":"10.1016\/j.celrep.2021.108996","article-title":"Avid binding by B cells to the Plasmodium circumsporozoite protein repeat suppresses responses to protective subdominant epitopes","volume":"35","author":"Chatterjee","year":"2021","journal-title":"Cell Rep"},{"key":"2026041420080403700_jiaf391-B43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm.4513","article-title":"A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein","volume":"24","author":"Tan","year":"2018","journal-title":"Nat Med"},{"key":"2026041420080403700_jiaf391-B44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12916-019-1277-x","article-title":"Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure","volume":"17","author":"Kurtovic","year":"2019","journal-title":"BMC Med"},{"key":"2026041420080403700_jiaf391-B45","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12916-022-02466-2","article-title":"Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children","volume":"20","author":"Feng","year":"2022","journal-title":"BMC Med"},{"key":"2026041420080403700_jiaf391-B46","doi-asserted-by":"crossref","first-page":"eabg2344","DOI":"10.1126\/scitranslmed.abg2344","article-title":"Functional human IgA targets a conserved site on malaria sporozoites","volume":"13","author":"Tan","year":"2021","journal-title":"Sci Transl Med"},{"key":"2026041420080403700_jiaf391-B47","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.4049\/jimmunol.142.10.3568","article-title":"The immunologic significance of variation within malaria circumsporozoite protein sequences","volume":"142","author":"De La Cruz","year":"1989","journal-title":"J Immunol"},{"key":"2026041420080403700_jiaf391-B48","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41591-020-0881-9","article-title":"Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs","volume":"26","author":"Murugan","year":"2020","journal-title":"Nat Med"},{"key":"2026041420080403700_jiaf391-B49","doi-asserted-by":"crossref","first-page":"e17454","DOI":"10.15252\/emmm.202317454","article-title":"Molecular and functional properties of human Plasmodium falciparum CSP C-terminus antibodies","volume":"15","author":"Oludada","year":"2023","journal-title":"EMBO Mol Med"},{"key":"2026041420080403700_jiaf391-B50","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1073\/pnas.1001323107","article-title":"A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray","volume":"107","author":"Crompton","year":"2010","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf391\/64080593\/jiaf391.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/1\/178\/64080593\/jiaf391.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/1\/178\/64080593\/jiaf391.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:15:38Z","timestamp":1776212138000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/233\/1\/178\/8237656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,19]]},"published-print":{"date-parts":[[2026,1,17]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf391","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,15]]},"published":{"date-parts":[[2025,8,19]]}}}